LXY3

LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer[1][2].

1095009-44-1

LXY2

12352209

Integrin

Cytoskeleton

Cancer-programmed cell death

Cancer

O=C1[C@]2(N(C[C@H](O)C2)C(CNC([C@H](CC3=CC([N+]([O-])=O)=C(O)C=C3)NC(CNC([C@@H](CC(O)=O)NC([C@H](N)CSSC[C@H](C(N)=O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)=O)=O)[H]

C32H43N11O15S2

885.88

[1]Wang Q, et al. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat Nanotechnol. 2024 Jan;19 (1) :95-105.|[2]Yao N. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem. 2009 Jan 8;52 (1) :126-33.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10934/

Peptides

No Development Reported